Stock MESO MESOBLAST LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Mesoblast Limited Share Price Nasdaq

Equities

MESO

US5907174016

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
6.24 USD +1.46% Intraday chart for Mesoblast Limited +19.77% +183.64%
04-01 ADRs End Higher; Connect Biopharma Climbs 26% DJ
03-28 ADRs End Lower; NuCana Slides 15% DJ

Financials

Sales 2024 * 11.52M 7.52M 602M Sales 2025 * 24.85M 16.23M 1.3B Capitalization 1.06B 693M 55.5B
Net income 2024 * -103M -67.28M -5.39B Net income 2025 * -121M -79.04M -6.33B EV / Sales 2024 * 96.9 x
Net Debt 2024 * 55.05M 35.96M 2.88B Net Debt 2025 * 93.28M 60.93M 4.88B EV / Sales 2025 * 46.5 x
P/E ratio 2024 *
-8.77 x
P/E ratio 2025 *
-8.64 x
Employees 83
Yield 2024 *
-
Yield 2025 *
-
Free-Float 87.79%
More Fundamentals * Assessed data

Chart Mesoblast Limited

Dynamic Chart

Latest news about Mesoblast Limited

ADRs End Higher; Connect Biopharma Climbs 26% DJ
ADRs End Lower; NuCana Slides 15% DJ
ADRs End Lower; Quhuo Drops 53% DJ
FDA Says Mesoblast Trial Data Sufficient to Support BLA Submission MT
Sector Update: Health Care Stocks Advance Late Afternoon MT
Top Midday Gainers MT
Sector Update: Health Care Stocks Steady Premarket Tuesday MT
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading MT
Top Premarket Gainers MT
Mesoblast Shares Jump After FDA Nod for Submission of Remestemcel-L Application DJ
Mesoblast to Resubmit Application for Potential Pediatric Treatment of Graft Versus Host Disease; Shares Gain Pre-Bell MT
United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease CI
Mesoblast Limited(ASX:MSB) added to S&P/ASX Emerging Companies Index CI
Mesoblast Raises AU$97 Million From Entitlement Offer, Institutional Placement MT
Mesoblast Raises AU$97 Million for Phase Three Registration Trials MT
More news

Latest transcript on Mesoblast Limited

Logo Mesoblast Limited
Mesoblast Limited, Q2 2024 Earnings Call, Feb 28, 2024
More transcripts

Analyst Recommendations on Mesoblast Limited

Fed Rate Outlook Weakens Exchange-Traded Funds, Equity Futures Premarket Thursday MT
Cantor Fitzgerald Adjusts Price Target on Mesoblast to $17 From $23, Maintains Overweight Rating MT
Maxim Downgrades Mesoblast to Hold From Buy MT
Piper Sandler Downgrades Mesoblast to Neutral From Overweight, Adjusts Price Target to $2 From $7 MT
William Blair Downgrades Mesoblast to Market Perform From Outperform MT
More recommendations

Press releases Mesoblast Limited

Reddit Inc. (NYSE: RDDT) Surges, Uncovering Undervalued Opportunities: DYAI, INBS, MESO, VTAK AQ
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) AQ
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer AQ
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD) AQ
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023 AQ
More press releases

News in other languages on Mesoblast Limited

MÄRKTE ASIEN/Etwas fester - Chinas Börsen hinken hinterher
EN DIRECT DES MARCHES : Renault, Vivendi, EssilorLuxottica, Kering, Vinci, Microsoft, Coca-Cola, Enel, Fedex...
MÄRKTE ASIEN/Corona-Sorgen lassen Anleger vorsichtig agieren
Aktien Schweiz: Wenig verändert - Anleger unschlüssig
MÄRKTE ASIEN/Wenig veränderte Börsen mit positiver Tendenz
More news

Quotes and Performance

1 day+1.46%
1 week+19.77%
Current month+24.55%
1 month+58.78%
3 months+240.98%
6 months+166.67%
Current year+183.64%
More quotes

Highs and lows

1 week
5.26
Extreme 5.26
6.36
1 month
3.91
Extreme 3.91
7.36
Current year
1.61
Extreme 1.61
7.36
1 year
1.61
Extreme 1.61
10.24
3 years
1.61
Extreme 1.61
17.98
5 years
1.61
Extreme 1.61
42.56
10 years
1.61
Extreme 1.61
54.02
More quotes

Managers and Directors - Mesoblast Limited

Managers TitleAgeSince
Silviu Itescu FOU
 Founder 67 07/06/04
Andrew Chaponnel DFI
 Director of Finance/CFO - 31/05/12
Dagmar Rosa-Bjorkeson COO
 Chief Operating Officer 60 23/07/20
Members of the board TitleAgeSince
Eric Rose CTO
 Chief Tech/Sci/R&D Officer 73 14/04/13
Joseph Swedish CHM
 Chairman 72 17/06/18
William Burns BRD
 Director/Board Member 76 05/03/14
More insiders

ETFs positioned on Mesoblast Limited

Name Weight AuM 1st Jan change Investor Rating
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
0.03% 2 M€ -.--%
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
0.03% 0 M€ 0.00% -
BMO MSCI INNOVATION INDEX ETF - CAD ETF BMO MSCI Innovation Index ETF - CAD
0.01% 7 M€ -.--% -
More ETFs positioned on Mesoblast Limited

Quotes

Date Price Change Volume
26/04/24 6.24 +1.46% 324,769
25/04/24 6.15 -1.13% 239,857
24/04/24 6.22 +3.67% 199,269
23/04/24 6 +8.50% 630,427
22/04/24 5.53 +6.14% 277,737

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes

Company Profile

Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.
Sector
Biotechnology & Medical Research
Calendar
28/05/2024 - Q3 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Mesoblast Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.93 AUD
Average target price
1.1 AUD
Spread / Average Target
+18.28%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MSB Stock
  4. MESO Stock